{"id":"abt-143","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABT-143 functions as a bispecific antibody designed to bind and modulate multiple immune pathways simultaneously, thereby overcoming tumor immune evasion. By targeting complementary checkpoint pathways, the drug aims to achieve synergistic T-cell activation and proliferation. This dual-targeting approach is intended to improve anti-tumor immunity compared to single-checkpoint inhibitors.","oneSentence":"ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:58:37.591Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT00463606","phase":"PHASE3","title":"A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":760},{"nctId":"NCT00812955","phase":"PHASE3","title":"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\"Bad Cholesterol\") and Triglycerides","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia","enrollment":474},{"nctId":"NCT00728780","phase":"PHASE1","title":"Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Adverse Events, Pharmacokinetic Variables","enrollment":32},{"nctId":"NCT00681395","phase":"PHASE1","title":"Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05","conditions":"Adverse Events, Pharmacokinetic","enrollment":64},{"nctId":"NCT00808678","phase":"PHASE1","title":"Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Healthy","enrollment":90},{"nctId":"NCT00826358","phase":"PHASE1","title":"Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Healthy","enrollment":90},{"nctId":"NCT00719693","phase":"PHASE1","title":"Assessment of the Effect of Food on ABT-143 Bioavailability","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Pharmacokinetic Variables","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABT-143","genericName":"ABT-143","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}